These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2162412)

  • 21. [Tumor markers for pancreatic and biliary tract cancer].
    Takezako Y; Okusaka T; Ueno H; Ikeda M; Morizane C; Najima M
    Gan To Kagaku Ryoho; 2004 Sep; 31(9):1443-6. PubMed ID: 15446574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Tumor markers in biliary tract cancer].
    Najima M; Okusaka T
    Nihon Rinsho; 2006 Jan; 64 Suppl 1():419-21. PubMed ID: 16457296
    [No Abstract]   [Full Text] [Related]  

  • 23. [Urinary free L-fucose (UFC) and urinary sulfated bile acids (U-SBA)].
    Mashige F
    Nihon Rinsho; 2005 Aug; 63 Suppl 8():774-8. PubMed ID: 16149638
    [No Abstract]   [Full Text] [Related]  

  • 24. The carbohydrate antigenic determinant 19-9 (CA 19-9): a monoclonal antibody defined tumor marker.
    DelVillano BC; Zurawski VR
    Lab Res Methods Biol Med; 1983; 8():269-82. PubMed ID: 6196588
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical evaluation of tissue polypeptide antigen (TPA) in the diagnosis of pancreatic carcinoma.
    Pasanen PA; Eskelinen M; Partanen K; Pikkarainen P; Penttila I
    Anticancer Res; 1993; 13(5C):1883-7. PubMed ID: 8267397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
    Ohtani M; Ido K; Kawamoto C; Kimura K
    Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
    [No Abstract]   [Full Text] [Related]  

  • 27. Standardization and quality control of tumour marker assays.
    Ward AM
    Dis Markers; 1991; 9(3-4):127-32. PubMed ID: 1813205
    [No Abstract]   [Full Text] [Related]  

  • 28. [Laboratory diagnosis of tumors of the pancreato-biliary area in patients with mechanical jaundice].
    Skvortsov SV; Lytsar' BN; Kalinin AV; Dolinskiĭ AG
    Klin Med (Mosk); 1992; 70(5-6):21-3. PubMed ID: 1279265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of serum TAC-41 in various digestive cancers].
    Sato S; Yamanaka T; Kimura K
    Rinsho Byori; 1989 Nov; 37(11):1259-62. PubMed ID: 2601083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The diagnostic significance of carbohydrate antigen CA 19-9 in serum and pancreatic juice in pancreatic carcinoma.
    Chen YF; Mai CR; Tie ZJ; Feng ZT; Zhang J; Lu XH; Lu GJ; Xue YH; Pan GZ
    Chin Med J (Engl); 1989 May; 102(5):333-7. PubMed ID: 2509154
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Tumor markers in the upper intestinal tract--stomach and pancreas].
    Pointner R; Conrad F; Schwab G
    Wien Klin Wochenschr; 1989 Jul; 101(14):482-4. PubMed ID: 2773485
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Occurrence of pancreatic tumor markers and diagnosis of small pancreatic tumors. 6). Application of tumor marker KM 01 analysis in the diagnosis of pancreatic neoplasms].
    Okumura S; Ohyanagi H; Saito Y
    Nihon Rinsho; 1986 Aug; 44(8):1834-42. PubMed ID: 3537375
    [No Abstract]   [Full Text] [Related]  

  • 33. [Pancreatic and biliary tract cancers].
    Sawada T; Yamada N; Hirakawa K
    Gan To Kagaku Ryoho; 2001 Jun; 28(6):865-71. PubMed ID: 11432359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The diagnostic significance of carbohydrate antigen 19-9 in pancreatic carcinomas].
    Chen YF
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Jun; 11(3):229-31. PubMed ID: 2529993
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical significance of des-gamma-carboxy prothrombin assay as a tumor marker].
    Yamano M
    Nihon Rinsho; 1990 Feb; 48 Suppl():999-1002. PubMed ID: 1693989
    [No Abstract]   [Full Text] [Related]  

  • 36. [2D3 series, MSW 113 and other monoclonal antibodies directed to type 1 chain carbohydrate antigens].
    Kannagi R; Takada A; Shigeta K; Itai S; Hashimoto K
    Nihon Rinsho; 1990 Feb; 48 Suppl():992-8. PubMed ID: 2355641
    [No Abstract]   [Full Text] [Related]  

  • 37. Immunohistochemical study of pancreatic cystadenocarcinoma.
    Motojima K; Tomioka T; Tsunoda T; Kanamatsu T
    Am J Gastroenterol; 1992 Jan; 87(1):43-7. PubMed ID: 1728123
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical relevance of the tumor marker CA 19-9 in the diagnosing and monitoring of pancreatic carcinoma.
    Safi F; Roscher R; Beger HG
    Bull Cancer; 1990; 77(1):83-91. PubMed ID: 2180502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CA 19-9 in serum and pancreatic juice: its role in the differential diagnosis of resectable pancreatic cancer from chronic pancreatitis.
    Malesci A; Evangelista A; Mariani A; Bersani M; Bonato C; Basilico M; Montorsi M; Beretta E
    Int J Pancreatol; 1988; 3 Suppl 1():S119-23. PubMed ID: 3209865
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical value of tumor marker CA50 and CA242 in digestive tract cancer].
    Huang C; Bei L; Liu T
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1998 Aug; 20(4):285-8. PubMed ID: 11367693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.